Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 4,205 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Injectable Placebo Clear all
Terminated Phase 2 Interventional Results available

A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects

NCT01235741
View directory record Official record
Conditions
Obesity
Interventions
Pramlintide+Metreleptin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
18
States / cities
Greenbrae, California • La Jolla, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes

NCT03311724
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
13
States / cities
Fresno, California • Los Angeles, California • Montclair, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.

NCT02247726
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Saline Placebo (0.5mL injection), RSV F vaccine (0.5mL injection)
Drug
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
7
States / cities
Nampa, Idaho • Hutchinson, Kansas • Kansas City, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated May 27, 2022 · Synced Oct 17, 2026, 5:15 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Dronabinol Naltrexone Treatment for Opioid Dependence

NCT01024335
View directory record Official record
Conditions
Opioid Dependence
Interventions
injectable naltrexone and dronabinol, Naltrexone and placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 17, 2026, 5:15 AM EDT
Recruiting Phase 2 Interventional

Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa

NCT07170917
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Brivekimig, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
17
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Northridge, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 17, 2026, 5:15 AM EDT
Active, not recruiting Early Phase 1 Interventional

Intralesional Cyclosporine for Alopecia Areata

NCT07029204
View directory record Official record
Conditions
Alopecia Areata
Interventions
CycloSPORINE Injectable Product, Saline Solution
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 17, 2026, 5:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Femoral Peri-arterial Local Anesthetic Injection Decreases Tourniquet Associated Ischemic Hypertension

NCT03390426
View directory record Official record
Conditions
Tourniquet Hypertension, Intraoperative Hypertension, Total Ankle Arthroplasty, Ankle Fusion
Interventions
Mepivacaine, Perifemoral Injection of Local Anesthetic, Saline
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 17, 2026, 5:15 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Preoperative Nerve Block for Rhinoplasty/Septoplasty

NCT03780478
View directory record Official record
Conditions
Nasal Fracture, Deviated Nasal Septum
Interventions
Nerve block, Placebo Saline Injection
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 17, 2026, 5:15 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma

NCT02336425
View directory record Official record
Conditions
Asthma
Interventions
QGE031, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Birmingham, Alabama • Kingwood, Texas • Plano, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2017 · Synced Oct 17, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)

NCT02662985
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
AIN457 (secukinumab), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Beverly Hills, California • Los Angeles, California • Wheaton, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Oct 17, 2026, 5:15 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

NCT03675308
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Placebo, Risankizumab
Biological
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
964 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
59
States / cities
Anniston, Alabama • Peoria, Arizona • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults

NCT03409276
View directory record Official record
Conditions
HIV Infections
Interventions
env (A,B,C,A/E)/gag (C) DNA Vaccine, gp120 (A,B,C,A/E) Protein Vaccine, Placebo, GLA-SE adjuvant
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
6
States / cities
Birmingham, Alabama • Decatur, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

Randomized, Double-blind, Vehicle Controlled, Repeat Dose Comparative Study in RA Patients Managed With DMARDs

NCT04286789
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Low dose ORTD-1, Low dose vehicle control, High dose ORTD-1, High dose vehicle control
Drug
Lead sponsor
Oryn Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Los Angeles, California • Tustin, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 17, 2026, 5:15 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Dose Escalation Trial of an Intravenous Antibiotic RC-01

NCT03832517
View directory record Official record
Conditions
Safety
Interventions
Single intravenous doses of RC-01, Single intravenous doses of placebo, Multiple intravenous doses of RC-01, Multiple intravenous doses of placebo
Drug
Lead sponsor
Recida Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 17, 2026, 5:15 AM EDT
Recruiting Phase 1Phase 2 Interventional

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne

NCT07013747
View directory record Official record
Conditions
Acne
Interventions
Acne mRNA vaccine, Placebo
Biological · Other
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
4
States / cities
Encino, California • Brandon, Florida • Jacksonville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only

NCT00518115
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Albiglutide (GSK716155) or exenatide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
158
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 142 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 17, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma

NCT00917384
View directory record Official record
Conditions
Gastric Cancer, Adenocarcinoma
Interventions
ramucirumab, Placebo, Best Supportive Care (BSC)
Biological · Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
14
States / cities
Bakersfield, California • La Jolla, California • Redlands, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 17, 2026, 5:15 AM EDT
Withdrawn Phase 2 Interventional

Botulinum Toxin Injection With Prostate Brachytherapy

NCT00681148
View directory record Official record
Conditions
Prostate Cancer, Lower Urinary Tract Symptoms, Radioactive Seed Implantation
Interventions
Botox injection, Saline injection
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 21, 2013 · Synced Oct 17, 2026, 5:15 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

NCT06891443
View directory record Official record
Conditions
Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Sensation Disorders, Vision Disorder, Neurological Manifestations, Eye Diseases, Hereditary, Eye Diseases, Eye Disorders Congenital, Retinal Disease
Interventions
sepofarsen, Placebo IVT
Drug · Other
Lead sponsor
Laboratoires Thea
Industry
Eligibility
6 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
San Francisco, California • Miami, Florida • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 17, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)

NCT02367040
View directory record Official record
Conditions
Lymphoma,Non-Hodgkin
Interventions
Copanlisib (Aliqopa, BAY80-6946), Placebo, Rituximab
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
16
States / cities
West Covina, California • Ashland, Kentucky • Louisville, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 17, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

NCT03989349
View directory record Official record
Conditions
Moderate-to-Severe Atopic Dermatitis
Interventions
Placebo, Nemolizumab
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
47
States / cities
Birmingham, Alabama • Guntersville, Alabama • Scottsdale, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Oct 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Double-Blind Multi-Dose Tolerability and Pharmacokinetic Study of Teduglutide

NCT00820885
View directory record Official record
Conditions
Pharmacokinetics and Safety of Elevated Doses
Interventions
teduglutide, tedguglutide
Drug
Lead sponsor
Shire
Industry
Eligibility
20 Years to 55 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety of USB005 in Healthy Volunteers

NCT03615196
View directory record Official record
Conditions
Healthy Volunteers
Interventions
USB005 (aclerastide) Ophthalmic Solution, USB005 Ophthalmic Solution Placebo
Drug
Lead sponsor
US Biotest, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Oct 17, 2026, 5:15 AM EDT
Terminated Phase 3 Interventional Results available

Study of OTO-104 in Subjects With Unilateral Meniere's Disease

NCT02717442
View directory record Official record
Conditions
Meniere's Disease
Interventions
OTO-104, Placebo
Drug
Lead sponsor
Otonomy, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Oct 17, 2026, 5:15 AM EDT